The optimal total body irradiation (TBI) regimen for unrelated donor bone marrow transplant (UD-BMT) is unknown.
Allogeneic hemopoietic stem cell transplant (HSCT) is an established treatment modality for a variety of congenital and acquired disorders of the hemopoietic system. 1 Being an HLA-genotypically identical sibling (SIB-HSCT) available for less than 30% of the potential transplant candidates, the use of alternative donors has been increasingly explored; 2 nowadays, HSCT from unrelated donors (UD-BMT) has become a steady approach and many patients have achieved complete immunologic tolerance and long survival. 3, 4 However, compared with SIB-HSCT, transplant from unrelated donors is associated with a high incidence of graft-versus-host disease (GVHD), morbidity and mortality. [5] [6] Total body irradiation (TBI) is included in the vast majority of conditioning regimens to be used in SIB and UD-BMT, although busulfan-based conditioning regimens have been extensively reported. 7 The aims of TBI are to destroy the host marrow to allow repopulation with donor marrow cells, to achieve immunosuppression in order to prevent graft rejection and to eradicate leukemia cell population. 8 TBI is generally delivered with a fractionated or hyperfractionated regimen in an attempt to increase the therapeutic ratio between disease cell killing and normal tissue toxicity. 9 Clinical studies have confirmed the therapeutic efficacy of once-a-day or multiple daily fractionated TBI regimens with lower risk of radiation-induced toxicity compared to single dose TBI. 8, 10 However, the optimal regimen of TBI with regard to total dose, number and type of fractionation remains controversial. 11 Besides, data concerning the role of TBI as a conditioning agent for UD-BMT patients are still limited and not definitive. 12 In theory, conditioning TBI for patients undergoing UD-BMT should induce an immunosuppressive effect towards matched or mismatched donor grafts and, meanwhile, eradicate malignant hematological clones without increasing the risk of moderate/severe acute GVHD. Given the higher antileukemic effect played in UD-BMT patients by genetic-disparity graft-versus-leukemia (GVL) reaction with respect to SIB-HSCT patients, 13 a lower TBI total dose might be delivered, in order to minimize the risk of radiation-induced morbidity which may lead to transplant-related mortality (TRM).
Here, we report the results from 99 patients who received an UD-BMT in Genoa after a conditioning regimen consisting of cyclophosphamide plus TBI. Two different TBI fractionation regimens were investigated from 1994 and 2001; hyperfractionated TBI was adopted until 1998. Given the observed 31% probability of TRM after hyperfractionated-TBI (HF-TBI), a lower fractionated dose of TBI (F-TBI) was introduced afterwards to replace the previous regimen. Although the different TBI schedules were administered sequentially over the 7 years and not randomized, we tried to retrospectively compare the two schedules; specifically, we aimed to investigate whether different levels of TBI dose delivered in different fractions may have a potential impact on transplant-related mortality (TRM), leukemia relapse rate (LRR) and overall survival (OS) in this series of patients undergoing UD-BMT.
Materials and methods

Patients
Between January 1994 and August 2001, 99 consecutive patients entered this study and received an unmanipulated allogeneic UD-BMT.
Clinical details and transplant-related parameters listed according to TBI schedule adopted are outlined in Table 1 . Out of 99 patients receiving UD-BMT, 68 (69%) were affected by chronic myeloid leukemia, 18 (18%) by acute lymphoblastic leukemia and 10 (10%) by acute myeloid leukemia.
Patients received a similar median transplant cell dose (3.3 ϫ 10 8 /kg in the F-TBI group and 3.2 ϫ 10 8 /kg in the HF-TBI group). Patients were cared for in single rooms with HEPA-filtered air from day Ϫ7 until at least day +30 when they were discharged, either to a conventional care unit or to the outpatient clinic. All patients received highdose immunoglobulin (HD IgG), 400 mg/kg/week from day Ϫ7 until day +100.
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HLA matching
All patients matched unrelated donors selected by the Italian Bone Marrow Donor Registry (IBMDR): donors were matched by serology for class I antigens, including split antigens and by molecular biology for class II, including high resolution sequence based typing (SBT) for DRB1. DQA, DQB, DPA and DPB mismatch was accepted, especially for advanced disease phase. Unmanipulated cells were given but care was taken to administer the highest possible cell dose. In the event of major ABO incompatibility, the marrow was not depleted of red cells, but isohemagglutinins were reduced in the patient to a titer р1:16 in saline, with one or two plasma exchanges performed on days Ϫ2 and Ϫ1 before transplant. Bone marrow was harvested from unrelated donors in the respective harvest center and transferred via courier to our unit without further manipulation. 6 
Conditioning regimen
Conditioning consisted of cyclophosphamide (Cy), 60 mg/kg/day on days Ϫ7 and Ϫ6, followed by total body irradiation (TBI) on days Ϫ 3, Ϫ2 and Ϫ1. Between January 1994 and April 1998, the TBI schedule was hyperfractionated with a total dose of 12 Gy (2 Gy, twice a day) in six fractions for 3 days (HF-TBI), whereas afterwards a fractionated TBI was adopted, consisting of a total dose of 9.90 Gy (3.30 Gy per day) in three fractions for 3 days (F-TBI). As outlined in the introduction, the change in TBI schedule was adopted in an attempt to reduce the observed incidence of TRM (31%) occurring after HF-TBI. The 9.9 Gy TBI schedule was chosen since, in our institution, this fractionation has been successfully used for HLA-matched SIB-HSCT since the early 1980s. 9 
TBI technique
Irradiation was performed with a 6 MV single energy Linear Accelerator (SL75, Philips, The Netherlands). TBI was delivered by anterior and posterior beam incidence (AP/PA setting). Every patient was treated in a semi-standing position alternately facing and turning their back to the beam. Gantry rotation was 270°and the collimator was open to its maximum field size, 40 ϫ 40 cm. The source axis distance was about 410 cm. Personalized lung shields were used to compensate for the different densities and to reduce the dose by 10% compared to the prescription point nominal dose. The dose prescription point was at navel level, on the patient central axis. In vivo dosimetry was performed for every patient, every treatment session, by using an ionization chamber (PTW DL4 Freiburg) surrounded by a build-up cup. 15 
GVHD prophylaxis
All patients received cyclosporin (CsA), 1 mg/kg by continuous i.v. infusion from day Ϫ7 to day Ϫ2, then 2 mg/kg Total body irradiation for UD-BMT R Corvò et al 719 i.v. from day Ϫ1 to day +20 and then 5-10 mg/kg/day p.o. from day +21 until at least day +365. Methotrexate (MTX) was given at the conventional dose of 15 mg/m 2 on day +1) and 10 mg/m 2 days +3, +6 and +11.
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CMV prophylaxis and treatment
All patients received foscarnet from day Ϫ7 to day +30 at a dose of 30 mg/kg twice daily, then 90 mg/kg/day, 5 days a week, from day +31 to day +100. Patients were monitored once a week from day +1 to day +30, then twice a week until day +100 for CMV antigenemia. CMV antigenemia was treated by adding ganciclovir (5-10 mg/kg/day for 15 days) to the prophylactic foscarnet. 16 
Statistical analysis
The chi-square test was used to test for differences between TBI subgroup characteristics and outcomes; the t-test was used for differences between continuous variables; KaplanMeyer actuarial survival plots were used for timedependent analysis (survival, transplant mortality and relapse). TRM was defined as death due to causes other than relapse. The Cox regression model was used to compare involved parameters, in a multivariate analysis and to rank their influence on transplant-related morbidity, relapse risk and survival, as the end-points. 17 Variables tested in the analysis were leukemia type, phase of disease at transplant, TBI schedule, donor sex and age, recipient sex and age, interval (days) between diagnosis and transplant, graft cell dose, and time period of transplant. Statistical analysis was carried out on the overall group of 99 patients, undergoing UD-BMT. Since, as shown in Table 1 , 68 patients had chronic myeloid leukemia, a detailed analysis of this subgroup was also performed separately to compare the two TBI regimens in a disease-homogeneous series of patients.
Results
As shown in Table 1 , 46 patients were conditioned with 12 Gy TBI (HF-TBI) and 53 patients with 9.90 Gy TBI (F-TBI). No statistical difference between two TBI subgroups was detected, although the F-TBI subgroup comprises a higher number of patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Fifty patients were in an early disease phase (26 patients in F-TBI subgroup and 24 patients in HF-TBI one); the median age of patients was 30 years (range 18-51 years), respectively 32 years (18-51) for F-TBI subgroup and 29 years (18-49) for HF-TBI one. For both subgroups, the median interval between diagnosis and UD-BMT was 993 days (range 201-4510 days).
At median follow-up of 22 months (58 months for HF-TBI group and 17 months for F-TBI group, respectively), 60 patients were alive (32 in the HF-TBI group and 28 in the F-TBI group). Of the 99 patients entered in this analysis, 75 (76%), respectively 36 (68%) in F-TBI and 39 (85%) in HF-TBI were alive and at risk of relapse at day 120 post HSCT; 16 of the 75 patients at risk (21%) relapsed, respectively 12 (33%) in F-TBI group and four (10%) in HF-TBI one (P = 0.01). As shown in Table 2 , acute GVHD (aGVHD) occurred at a median interval from UD-BMT of 14 days (range 5-70 days). aGVHD was scored as grade 0-I, grade II, grade III-IV in 40%, 41% and 19% in F-TBI group respectively, vs 41%, 37% and 22% in HF-TBI group (P = NS). Chronic GVHD (cGVHD) was scored as extensive in three patients (5.7%) in F-TBI and in six patients (13%) in HF-TBI (P = 0.1). Thirty-nine patients have died, respectively 14 (30%) in HF-TBI group and 25 (47%) in F-TBI one (P = 0.01). Causes of death were leukemia (n = 5), acute GVHD (n = 8), interstitial pneumonitis (n = 3), acute GVHD and interstitial pneumonitis (n = 1), infection (n = 12), ARDS (n = 1), chronic GVHD (n = 7) and multiorgan failure (n = 2). Table 3 shows the causes of death according to the TBI regimen adopted.
Transplant-related mortality
Twenty-nine (29%) patients, 16 (36%) in the F-TBI group and 13 (28%) in HF-TBI respectively, have died of transplant-related complications (TRM). The actuarial 5-year TRM was 41% (95% CL: 28%-59%) in the F-TBI and 31% (95% CL: 19%-48%) in the HF-TBI series (P = 0.1) (Figure Table 3 Causes of death according to different TBI group
HF-TBI F-TBI n = 46 n = 53
Causes of death n = 14 n = 25 Leukemia 1 (7%) 4 (16%) Acute 1). When the analysis was restricted to the patients with CML (n = 68), the 5-year TMR was 41% (95% CL: 35-46) for F-TBI patients and 27% (95% CL: 15-46) for the HF-TBI group. This difference in TRM reached statistical significance (P = 0.03).
Leukemia relapse
Overall, the actuarial 5-year leukemia relapse rates were 31% (95% CL: 19%-50%) for F-TBI group and 13% (95% CL: 5%-30%) for HF-TBI one (P = 0.04) (Figure 2 ). For CML patients, the corresponding LRRs were 32% (95% CL: 12%-55%) for F-TBI group and 11% (95% CL: 4%-30%) for HF-TBI patients (P = 0.03).
Overall survival
The actuarial 5-year survival was 57% for all patients (n = 99). The analysis performed according to TBI schedule showed that overall survival for patients with F-TBI was significantly (P = 0.03) lower (51%-95% CL: 37-64) than that (68%-95% CL: 51-79) observed for patients treated with HF-TBI ( Figure 3 ). For CML, OS rates were respectively 54% (95% CL: 45-66) for patients treated with F-TBI and 74% (95% CL: 56-85) for those treated with HF-TBI (P = 0.02) (Figure 4) .
TBI schedule and phase of leukemia
TRM and OS rates were analyzed for the entire group (n = 99), as well as for CML subgroup (n = 68) according either to the phase of disease at the time of transplant or to TBI regimen. The results showed that actuarial probabilities of outcome were not statistically different between patients transplanted in early or advanced disease phase (Table 4) . However, advanced disease was correlated with a higher leukemia relapse rate; the lower (6%) incidence of leukemia relapse was evident for patients with early state disease conditioned with HF-TBI, whereas the higher LRR (43%) was observed for patients with advanced disease treated with F-TBI (Table 4) . This difference in the incidence of leukemia relapse remained similar when the patients with CML were analyzed ( Table 5) . Table 6 shows the results obtained from Cox multivariate analysis performed to determine which factors could independently influence transplant-related mortality, leukemia relapse risk and overall survival. Analysis showed that F-TBI emerged as an independent factor adversely affecting OS (P = 0.04) and LRR (P = 0.03). Graft cell dose was also an independent factor significantly affecting overall survival (P = 0.02), whereas phase of disease affected LRR (P = 0.04).
Multivariate analysis
Regarding TRM, graft cell dose was the only independent significant (P = 0.01) factor emerging on multivariate analysis.
Discussion
These results show that a lower fractionated dose of TBI appeared to be significantly less effective in leukemia eradication and was associated with a worse overall survival when compared to a higher hyperfractionated radiation Table 6 Cox multivariate analysis for all 99 patients submitted to UD-BMT Bone Marrow Transplantation dose; this preliminary finding appears to suggest that variation in the delivery of TBI dose may affect the prognosis of patients with leukemia receiving similar transplant procedures for UD-BMT. The low dose of fractionated TBI was introduced in our institution for UD-BMT patients in an attempt to reduce the transplant-related mortality observed in about one-third of patients previously conditioned with the hyperfractionated 12 Gy TBI dose. The rationale we followed to explore giving a lower dose of TBI was based on several convincing reasons. First, the low dose F-TBI schedule has been successfully used for two decades in the conditioning of SIB-HSCT patients, providing good clinical outcome comparable with data in the literature and resulting in low radiation-induced toxicity. 6 Second, we hypothesized that a lower dose of radiation therapy would neither have induced minor leukemia cell killing nor impaired clinical outcome since the graft-versus-leukemia (GVL) phenomenon in UD-BMT patients seems to be magnified; 13 of note, studies from Seattle 2,3 have shown decreased relapse rates in children with acute lymphoblastic leukemia receiving unrelated transplants against those receiving an HLA-identical sibling transplant. To explain this finding, the authors suggested that these results were consistent with the increased antileukemic activity of allogeneic grafts from unrelated donors. Third, our choice of a lower dose of TBI was further influenced by results obtained from a recent meta-analysis carried out to evaluate the significant determinants of occurrence of solid cancers in long-term survivors after bone marrow transplantation. This analysis has shown that a total dose of TBI lower than 10 Gy correlated with a lower risk of developing thyroid, salivary gland, bone and connective tissue cancers. 18 Despite our hypotheses, the results provided by our analysis have provided unexpected and interesting findings. First, our comparison conducted on the whole series of 99 revealed that the low-dose TBI regimen was not associated with a lower TRM with respect to hyperfractionated high dose TBI. This observation was also evident when the study was restricted to the subgroup of patients with chronic myeloid leukemia. Also, although not significant, a trend for a higher incidence of mortality related to acute GVHD and interstitial pneumonitis was recorded in the group of patients irradiated with the F-TBI regimen. In addition, our data showed that the low-dose F-TBI regimen was associated with an increased leukemia relapse rate. This evidence was confirmed by multivariate analysis where a low TBI dose emerged as an independent variable adversely affecting the probability of leukemia-free survival. This finding seems to indicate that, even if the GVL effect plays a major role in outcome after UD-BMT, the total dose of TBI is strictly correlated with the eradication process of hemopoietic malignancies. We observed that patients receiving the hyperfractionated dose of 12 Gy had a trend towards a higher probability of developing chronic GVHD, considered the clinical expression of GVL. 1, 5, 14 As previously reported in transplanted patients with acute lymphoblastic leukemia patients, 15 HF-TBI dose may increase the capacity of donor marrow to engraft, either because of improved immunosuppression or because of a reduced incidence of minor residual host hemopoiesis which may be associated with a reduced relapse rate. 19 Our preliminary suggestions seem to be in contrast to the results obtained from a series of 116 patients receiving allogeneic bone marrow transplants from siblings or unrelated donors and conditioned with three different fractionated TBI regimens up to the total doses respectively of 10 Gy, 12 and 13.5 Gy. 11 The authors have found that delivery of a fractionated TBI dose of more than 10 Gy may not necessarily be associated with a better outcome: unexpectedly, TBI dose was inversely correlated with overall survival, raising the suggestion that higher TBI doses may even be deleterious, especially for older patients.
These controversial results show that nowadays the optimal TBI schedule has still not been defined. However, experimental and clinical data have strongly stated that fractionation and/or low-dose rate reduce major TBI toxicities. 20 Meanwhile, some suggestions do exist that a reduced antileukemic effect may also emerge with fractionated low dose irradiation. 10, 19 The role of total TBI dose has been clearly proven in T cell-depleted grafts where relapse rate and rejection incidence were lower if hyperfractionated, increased TBI doses (up to 15.75 Gy) were used. 8 20 At present, few data 3, 4, 21 have been reported with regard to the role played by TBI in the conditioning of patients undergoing UR-BMT: with this transplant procedure it is likely that low-dose fractionated TBI may be under a level of 'threshold of efficacy' and a higher total dose of radiation is needed.
In our opinion, further studies should be carried out to evaluate the specific role played by different TBI doses in various transplant conditioning regimens. Nevertheless, as preliminary conclusions, we suggest that lowering the TBI dose in UD-BMT may be deleterious because outcome may be compromised. In our analysis, the impaired overall survival obtained in the lower dose F-TBI group was likely to have been a combined result of the higher TRM rate and the increased leukemia relapse rate observed with this regimen when compared to the high-dose HF-TBI group. Interestingly, although it needs to be confirmed on a larger group of irradiated patients, the different clinical outcomes seen after these two TBI groups correlate well with mathematical data provided by a radiobiological model of toxicity/efficacy of both radiation regimens used. 10, 22, 23 In conclusion, this study showed that a lower F-TBI dose appeared to be significantly less effective in leukemia eradication than a higher HF-TBI dose. Also, overall survival was significantly worse in patients conditioned with F-TBI. On multivariate analysis lower TBI dose was a significant factor adversely affecting overall survival and probability of leukemia-free survival. Although further trials are needed comparing different TBI doses before any definitive conclusions can be drawn, these results suggest that variations in the delivery of fractionated TBI might affect prognosis in patients receiving UD-BMT.
